Authors: J. Starý 1; P. Gajdoš 2; O. Hrušák 3; D. Pospíšilová 4; J. Hak 5; L. Kopečná 6; K. Michalová 7 Authors‘ workplace: II. dětská klinika UK 2. LF a FN Motol, Praha, 2 Státní zdravotní ústav, Praha, 3 Imunologický ústav UK 2. LF a FN Motol, Praha, 4 Dětská klinika FN Olomouc, 5 Dětská klinika FN Hradec Králové, 6 I. dětská interní a onkologická klinika FN Brno, 7 Centrum 1 Published in: Transfuze Hematol. dnes,, 2002, No. 2, p. 55-58. Category:
Acute lymphoblastic leukaemia (ALL)derived from mature B-cells is in fact generalized Burkitt ´slymphoma.Leukemic blasts are classified as L3 according to the FAB morphological classification.Theyare characterized by the presence of the surface immunoglobulins,most often IgM,and by a highproliferative rate.Current treatment comprising short blocks of intensive chemotherapy improvedremarkably the prognosis of this rare disease.Between VI/1990-XII/2000,ALL was diagnosed in 671children and adolescents aged 0 –18 years in the Czech Republic.B-ALL was found in 9 children (1.3 %).Complete remission was achieved in 77.8 %children.Four patients (44.4 %)suffered from early renalfailure which developed as a result of the tumour lysis syndrome.Neither death in remission nor relapsewere seen in this small group of patients.With a median follow-up of 3,7 years,the probability ofevent-free-survival is 75 %(SE 15 %).Therapeutic results of B-ALLin the Czech Republic are comparableto the results of the leading leukaemic study groups in the world.
Key words: acute lymphoblastic leukaemia,mature-B-cells,treatment,children
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
